What happened
Isomorphic Labs, the London-headquartered AI drug discovery company founded by Demis Hassabis, has closed a $5bn Series C round, Tech.eu reported. The raise comes six months after the company completed a $2.1bn Series B. California venture firms Greenoaks and Sequoia co-led the deal, joined by Andreessen Horowitz, Thrive Capital, Alphabet, Alphabet's GV and CapitalG, Temasek and the Sovereign AI fund.
The company said the capital will support further AI development and the build-out of clinical development infrastructure as it moves drug candidates into clinical trials. It plans to keep improving IsoDDE, its proprietary drug design engine, push into new areas of biology with more advanced models, and form a network of partners aimed at better understanding the mechanisms of disease.
Hassabis, who is also chief executive, said the round would help the company develop foundational biology models, deepen its understanding of disease at a systemic level and advance its first therapeutic programs to the clinic. President Max Jaderberg said the company's models were producing repeatable scientific gains each week that translate into improved molecular profiles for potential medicines.
Context
Isomorphic was spun out of Google DeepMind and draws on software developed there, including AlphaFold, the Nobel Prize-winning system that predicts protein structures. Its research focuses on cancer and immune disorders, and it is scaling both IsoDDE and a pipeline of AI-designed therapeutic candidates.
ブリーフィング
1週間のテックニュースを1通のメールで。
読む価値のある記事を毎週お届けします。配信停止はいつでも可能です。
